Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

AbbVie’s Anti-Tau Antibody Enters Phase II Clinical Trials for Alzheimer’s Disease

XTALKS VITALS NEWS

Alzheimer's Disease

While tau is thought to stabilize neuronal structures, its abnormal accumulation has been associated with a number of neurodegenerative disorders, including Alzheimer’s disease and PSP.

Share this!

January 26, 2017 | by Sarah Hand, M.Sc.

AbbVie has commenced two Phase II clinical trials for the company’s investigational anti-tau antibody, ABBV-8E12. The drug will be evaluated in patients with early-stage Alzheimer’s disease, along with patients diagnosed with progressive supranuclear palsy (PSP).

PSP is a progressive neurodegenerative disorder which primarily affects those over the age of 60. Due to the similarity of symptoms – including balance problems and changes in movement – compared to Parkinson’s disease, PSP is often initially misdiagnosed.

Since no effective treatment exists for PSP, the US Food and Drug Administration (FDA) has granted Orphan Drug Designation and Fast Track Designation to ABBV-8E12. The European Medicines Agency (EMA) has granted orphan drug status to AbbVie’s investigational antibody for the treatment of PSP.



“We see potential in ABBV-8E12 and tau-focused approaches to progressive neurodegenerative diseases, such as early Alzheimer's disease and PSP,” said Eric Karran, vice president, Foundational Neuroscience Center, AbbVie. “The initiation of the Phase 2 clinical trial programs and the FDA's Fast Track Designation for PSP signify important steps forward in AbbVie's ongoing commitment to investigating innovative scientific approaches with the hope of bringing new treatment options to patients.”

ABBV-8E12 is a humanized antibody designed to target the tau protein. While tau is thought to stabilize neuronal structures, its abnormal accumulation has been associated with a number of neurodegenerative disorders, including Alzheimer’s disease and PSP.

Pre-clinical and phase I studies showed positive results for ABBV-8E12, supporting the further development of the anti-tau antibody in PSP and Alzheimer’s disease. Phase I results for ABBV-8E12 were presented at last year’s Clinical Trials on Alzheimer's Disease (CTAD) annual meeting.

The safety and efficacy of ABBV-8E12 will be assessed in 180 adult patients with PSP. The Phase II Alzheimer’s trial will enroll 400 patients with early-stage disease, to assess the antibody’s ability to slow disease progression.


Keywords: Tau, Alzheimer's Disease, Clinical Trials


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.